Comparative Study of 250 mg/day Terbinafine and 100 mg/day Itraconazole for the Treatment of Cutaneous Sporotrichosis
- 264 Downloads
Itraconazole is currently used for the treatment of cutaneous sporotrichosis. Terbinafine at a daily dose of 250 mg has been successfully applied to the treatment of cutaneous sporotrichosis.
To compare the efficacy of 250 mg/day terbinafine and 100 mg/day itraconazole for the treatment of cutaneous sporotrichosis.
Materials and methods
A bidirectional cohort study was conducted on 55 patients receiving 250 mg/day terbinafine and 249 patients receiving 100 mg/day itraconazole. The latter patients were matched for age and clinical form to the terbinafine group at a ratio of 5:1. Sporothrix schenckii was isolated by culture from all patients (age range: 18–70 years), who were submitted to the standard care protocol consisting of clinical and laboratory evaluation and periodic visits.
Cure was observed in 51 (92.7%) patients of the terbinafine group and 229 (92%) of the itraconazole group within a similar mean period of time (11.5 and 11.8 weeks, respectively). An increase in the terbinafine dose to 500 mg was necessary in two patients due to the lack of a response, and one patient presented recurrence. In the itraconazole group, two patients required a dose increase and three presented recurrence. Adverse events were equally frequent among patients receiving terbinafine (n = 4, 7.3%) and itraconazole (n = 19, 7.6%) and were generally mild without the need for drug discontinuation, except for two patients of the itraconazole group.
Terbinafine administered at a daily dose of 250 mg is an effective and well-tolerated option for the treatment of cutaneous sporotrichosis.
KeywordsSporotrichosis Itraconazole Terbinafine Treatment
- 7.Song Y, Zhong SX, Yao L, Cai Q, Zhou JF, Liu YY, Huo SS, Li SS. Efficacy and safety of itraconazole pulses vs. continuous regimen in cutaneous sporotrichosis. J Eur Acad Dermatol Venereol. 2010. Epub ahead of print.Google Scholar
- 8.Micromedex DrugDex. E MARTINDALE Itraconazole. The Complete Drug Reference http://www.thomsonhc.com/hcs/librarian/ND_PR/Main/SBK/2/PFPUI/BpY1SQ1yTn4wf/ND_PG/PRIH/CS/97A06F/ND_T/HCS/ND_P/Main/DUPLICATIONSHIELDSYNC/5B2E6F/ND_B/HCS/PFActionId/hcs.common.RetrieveDocumentCommon/DocId/2679p/ContentSetId/30/SearchTerm/Itraconazole/SearchOption/BeginWithReference. Accessed 12 Dec 2008.
- 9.Chapman SW, Pappas P, Kauffmann C, Smith EB, Dietze R, Tiraboschi-Foss N, Restrepo A, Bustamante AB, Opper C, Emady-Azar S, Bakshi R. Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1,000 mg day(−1)) in the treatment of cutaneous or lymphocutaneous sporotrichosis. Mycoses. 2004;47(1–2):62–8.PubMedCrossRefGoogle Scholar
- 21.Micromedex DrugDex E MARTINDALE Terbinafine. The Complete Drug Reference http://www.thomsonhc.com/hcs/librarian/ND_PR/Main/SBK/2/PFPUI/BpY1SQ1yTn4wf/ND_PG/PRIH/CS/97A06F/ND_T/HCS/ND_P/Main/DUPLICATIONSHIELDSYNC/5B2E6F/ND_B/HCS/PFActionId/hcs.common.RetrieveDocumentCommon/DocId/2679p/ContentSetId/30/SearchTerm/terbinafine/SearchOption/BeginWithReference. Accessed 12 Dec 2008.
- 27.Kwon-Chung KJ, Benett JE. Sporotrichosis. In: Kwon-Chung KJ, Benett JE, editors. Medical mycology. Philadelphia: Lea and Febiger; 1992. p. 707.Google Scholar
- 30.Perez A. Terbinafine: a broad new spectrum of indications in several subcutaneous and systemic mycoses and parasitic diseases. Mycoses. 1999;42:150–1.Google Scholar
- 31.Sampaio S, Lacaz C, Almeida F. Clinical aspects on sporotrichosis in São Paulo. Rev Hosp Clin Fac Med São Paulo. 1954;9:391–402.Google Scholar